These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 31736084)
1. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status. Abdel-Sater F; Najar M; Fayyad-Kazan H J Cell Physiol; 2020 Jun; 235(6):5204-5212. PubMed ID: 31736084 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression. Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805 [TBL] [Abstract][Full Text] [Related]
3. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer. Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393 [TBL] [Abstract][Full Text] [Related]
4. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival. Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710 [TBL] [Abstract][Full Text] [Related]
5. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers. Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359 [TBL] [Abstract][Full Text] [Related]
6. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655 [TBL] [Abstract][Full Text] [Related]
8. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366 [TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer. Song W; Tang L; Xu Y; Xu J; Zhang W; Xie H; Wang S; Guan X Sci Rep; 2017 Feb; 7():42319. PubMed ID: 28176879 [TBL] [Abstract][Full Text] [Related]
10. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291 [TBL] [Abstract][Full Text] [Related]
11. miRNA-135b Contributes to Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243 [TBL] [Abstract][Full Text] [Related]
12. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer. Thakur S; Grover RK; Gupta S; Yadav AK; Das BC PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381 [TBL] [Abstract][Full Text] [Related]
13. Dysregulation of microRNAs in triple-negative breast cancer. Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413 [TBL] [Abstract][Full Text] [Related]
14. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Hu J; Xu J; Wu Y; Chen Q; Zheng W; Lu X; Zhou C; Jiao D Tumour Biol; 2015 Jan; 36(1):251-8. PubMed ID: 25238878 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients. Gaceb H; Cherbal F; Bakour R; Ould-Rouis A; Mahfouf H Pathol Oncol Res; 2018 Apr; 24(2):297-308. PubMed ID: 28478614 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA in breast cancer: The association with BRCA1/2. Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741 [TBL] [Abstract][Full Text] [Related]
17. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis. Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Gao S; Wang Y; Wang M; Li Z; Zhao Z; Wang RX; Wu R; Yuan Z; Cui R; Jiao K; Wang L; Ouyang L; Liu R Oncotarget; 2017 Jun; 8(25):41451-41464. PubMed ID: 28562349 [TBL] [Abstract][Full Text] [Related]
19. miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers. Fkih M'hamed I; Privat M; Trimeche M; Penault-Llorca F; Bignon YJ; Kenani A Pathol Oncol Res; 2017 Oct; 23(4):815-827. PubMed ID: 28101798 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK; BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]